This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An author's correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2504-2509, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of Streptococcus pneumoniae: Results of a Canadian National Surveillance Study

George G. Zhanel,1,2,3,4 James A. Karlowsky,1,2,4 Lorraine Palatnick,3 Laverne Vercaigne,2 Donald E. Low,5,dagger The Canadian Respiratory Infection Study Group,Dagger and Daryl J. Hoban1,4,dagger ,*

Department of Medical Microbiology, Faculty of Medicine,1 and Faculty of Pharmacy,2 University of Manitoba, and Departments of Medicine3 and Clinical Microbiology,4 Health Sciences Centre, Winnipeg, Manitoba, and Department of Microbiology, Mt. Sinai Hospital, Toronto, Ontario,5 Canada

Received 10 March 1999/Returned for modification 29 June 1999/Accepted 22 July 1999

From October 1997 to November 1998, 1,180 respiratory tract isolates of Streptococcus pneumoniae were collected from 18 medical centers in 9 of the 10 Canadian provinces. Penicillin-intermediate and -resistant isolates occurred at rates of 14.8 and 6.4%, respectively, and these rates varied considerably by geographic region. Trimethoprim-sulfamethoxazole, tetracycline, and macrolide rates of nonsusceptibility were 12.2, 10.6, and 8.0 to 9.3%, respectively. The most potent agents studied were newer fluoroquinolones.

* Corresponding author. Mailing address: Department of Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook St., Winnipeg, Manitoba R3A 1R9, Canada. Phone: (204) 787-1191. Fax: (204) 787-4699. E-mail: dhoban{at}hsc.mb.ca.

dagger Member of The Canadian Respiratory Infection Study Group.

Dagger Other members of The Canadian Respiratory Infection Study Group are listed in the appendix.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2504-2509, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Granger, D., Boily-Larouche, G., Turgeon, P., Weiss, K., Roger, M. (2006). Molecular characteristics of pbp1a and pbp2b in clinical Streptococcus pneumoniae isolates in Quebec, Canada. J Antimicrob Chemother 57: 61-70 [Abstract] [Full Text]  
  • Granger, D., Boily-Larouche, G., Turgeon, P., Weiss, K., Roger, M. (2005). Genetic analysis of pbp2x in clinical Streptococcus pneumoniae isolates in Quebec, Canada. J Antimicrob Chemother 55: 832-839 [Abstract] [Full Text]  
  • Zhanel, G. G., Johanson, C., Hisanaga, T., Mendoza, C., Laing, N., Noreddin, A., Wierzbowski, A., Hoban, D. J. (2004). Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother 54: 1072-1077 [Abstract] [Full Text]  
  • Canton, R., Morosini, M., Enright, M. C., Morrissey, I. (2003). Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 52: 944-952 [Abstract] [Full Text]  
  • Zhanel, G. G, Noreddin, A. M (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: In Vitro Models. The Annals of Pharmacotherapy 37: 1331-1334 [Full Text]  
  • Zhanel, G. G., DeCorby, M., Noreddin, A., Mendoza, C., Cumming, A., Nichol, K., Wierzbowski, A., Hoban, D. J. (2003). Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52: 83-88 [Abstract] [Full Text]  
  • Zhanel, G. G., Palatnick, L., Nichol, K. A., Bellyou, T., Low, D. E., Hoban, D. J. (2003). Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47: 1867-1874 [Abstract] [Full Text]  
  • Zhanel, G. G., Palatnick, L., Nichol, K. A., Low, D. E., The CROSS Study Group,, , Hoban, D. J. (2003). Antimicrobial Resistance in Haemophilus influenzae and Moraxella catarrhalis Respiratory Tract Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47: 1875-1881 [Abstract] [Full Text]  
  • Liebowitz, L D, Slabbert, M, Huisamen, A (2003). National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents. J. Clin. Pathol. 56: 344-347 [Abstract] [Full Text]  
  • Malcolm, C., Marrie, T. J. (2003). Antibiotic Therapy for Ambulatory Patients With Community-Acquired Pneumonia in an Emergency Department Setting. Arch Intern Med 163: 797-802 [Abstract] [Full Text]  
  • Noreddin, A. M., Roberts, D., Nichol, K., Wierzbowski, A., Hoban, D. J., Zhanel, G. G. (2002). Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef(A) or erm(B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations. Antimicrob. Agents Chemother. 46: 4029-4034 [Abstract] [Full Text]  
  • Nichol, K. A., Zhanel, G. G., Hoban, D. J. (2002). Penicillin-Binding Protein 1A, 2B, and 2X Alterations in Canadian Isolates of Penicillin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 3261-3264 [Abstract] [Full Text]  
  • Zhanel, G. G., Roberts, D., Waltky, A., Laing, N., Nichol, K., Smith, H., Noreddin, A., Bellyou, T., Hoban, D. J. (2002). Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 49: 807-812 [Abstract] [Full Text]  
  • Fuchs, P. C., Barry, A. L., Brown, S. D. (2002). In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime. J Antimicrob Chemother 49: 399-401 [Abstract] [Full Text]  
  • Mitten, M. J., Meulbroek, J., Nukkala, M., Paige, L., Jarvis, K., Oleksijew, A., Tovcimak, A., Hernandez, L., Alder, J. D., Ewing, P., Or, Y. S., Ma, Z., Nilius, A. M., Mollison, K., Flamm, R. K. (2001). Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections. Antimicrob. Agents Chemother. 45: 2585-2593 [Abstract] [Full Text]  
  • Hoban, D. J., Wierzbowski, A. K., Nichol, K., Zhanel, G. G. (2001). Macrolide-Resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef(A) and erm(B) and Susceptibilities to Ketolides. Antimicrob. Agents Chemother. 45: 2147-2150 [Abstract] [Full Text]  
  • Karlowsky, J. A., Nealy, L., Sahm, D. F., Thornsberry, C., Jones, M. E., Pfaller, M. A., Jones, R. N. (2001). Trends in Ciprofloxacin Nonsusceptibility and Levofloxacin Resistance among Streptococcus pneumoniae Isolates in North America. J. Clin. Microbiol. 39: 2748-2750 [Full Text]  
  • Zhanel, G. G., Walters, M., Laing, N., Hoban, D. J. (2001). In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 47: 435-440 [Abstract] [Full Text]  
  • Granizo, J. J., Aguilar, L., Casal, J., Garcia-Rey, C., Dal-Re, R., Baquero, F. (2000). Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and {beta}-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 46: 767-773 [Abstract] [Full Text]  
  • Hoban, D. J., Bouchillon, S. K., Karlowsky, J. A., Johnson, J. L., Butler, D. L., Miller, L. A., Poupard, J. A., The Gemifloxacin Surveillance Study Research Group, (2000). A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniae Isolates from across Europe, North America, and South America. Antimicrob. Agents Chemother. 44: 3008-3011 [Abstract] [Full Text]  
  • Preston, D. A., Turnak, M. R., Jacobs, M. R., Appelbaum, P. C., Zhanel, G. G., Low, D. E., Craig, W. (2000). Assumed versus Approved Breakpoints. Antimicrob. Agents Chemother. 44: 3243-3245 [Full Text]  
  • Jones, R. N., Pfaller, M. A. (2000). Macrolide and Fluoroquinolone (Levofloxacin) Resistances among Streptococcus pneumoniae Strains: Significant Trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). J. Clin. Microbiol. 38: 4298-4299 [Full Text]  
  • Bartlett, J. G. (2000). Update in Infectious Diseases. ANN INTERN MED 133: 285-292 [Full Text]  
  • (1999). Penicillin-Resistant Pneumococci an Increasing Problem in Canada. JWatch Infect. Diseases 1999: 11-11 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»